Our finding that IBC cells are sensitive to HDAC6 inhibition provides a foundation to rapidly develop novel, efficient, and well-tolerated targeted therapy strategies for IBC patients. The gene discussed is HDAC6; the disease is inflammatory breast carcinoma.